Open access
Oct 2026
InDuRanS: neoadjuvant immunochemotherapy followed by surgery or definitive chemoradiotherapy and consolidation durvalumab in resectable and borderline resectable stage IIB–IIIA/B non-small-cell lung cancer
Background The optimal integration of surgery and definitive chemoradiotherapy (CRT) following modern neoadjuvant immunochemotherapy in stage IIB–IIIA/B non-small-cell lung cancer (NSCLC) remains controversial. Although immune checkpoint inhibitors have substantially improved outcomes in both resectable and unresectabl...
E. Gkika, Cornelius F. Waller, C. Dejonckheere et al.
· Frontiers in Oncology · 1 citation